Paul D. Burgess - 04 Aug 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Chief Business Development and Strategic Operations Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 04 Aug 2023
Net transactions value: +$501,794
Form type: 4
Filing time: 07 Aug 2023, 17:11:49 UTC
Previous filing: 06 Jul 2023
Next filing: 21 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Purchase	$501,794	+21,880		$22.93	21,880	04 Aug 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.85 - $22.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.85 - $22.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Business Development and Strategic Operations Officer